CP-533, 536 + Placebo + CP-533,536 + CP-533,536 + CP-533,536
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tibial Fractures
Conditions
Tibial Fractures
Trial Timeline
Jan 1, 2008 → May 1, 2010
NCT ID
NCT00533377About CP-533, 536 + Placebo + CP-533,536 + CP-533,536 + CP-533,536
CP-533, 536 + Placebo + CP-533,536 + CP-533,536 + CP-533,536 is a phase 2 stage product being developed by Pfizer for Tibial Fractures. The current trial status is completed. This product is registered under clinical trial identifier NCT00533377. Target conditions include Tibial Fractures.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00533377 | Phase 2 | Completed |
Competing Products
2 competing products in Tibial Fractures